Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nazanin Majd

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Expert Opinion on Pharmacotherapy|July 3, 2019
Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastomaNazanin Majd, John de Groot
Current Treatment Options in Oncology|June 26, 2019
Updates on Management of Adult MedulloblastomaNazanin Majd, Marta Penas-Prado
Advances in Experimental Medicine and Biology|April 18, 2020
Immunotherapy for Neuro-OncologyNazanin Majd, Pushan Dasgupta, John de Groot
International Journal of Molecular Sciences|January 5, 2021
Molecular Mechanisms of Treatment Resistance in GlioblastomaAlexander Ou, W K Alfred Yung, Nazanin Majd
Current Opinion in Neurology|October 1, 2019
The path forward for anti-programmed cell death-1 therapy in gliomasNazanin Majd, Carlos Kamiya-Matsuoka, John de Groot
Journal of Immunotherapy and Precision Oncology|June 6, 2022
The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in GliomasNazanin Majd, Timothy A Yap, W K Alfred Yung, et al.
International Journal of Molecular Sciences|March 19, 2020
Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment ResistanceSabbir Khan, Sandeep Mittal, Kain McGee, et al.
Cancers|July 15, 2026
Role of Surgery in the Multimodal Treatment of Pituitary Carcinoma: A Retrospective Single-Institution Case SeriesChristina Abi Faraj, Maxwell Tran, Sherise D Ferguson, et al.
Cancers|September 14, 2019
Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long StoryRand Naffouje, Punita Grover, Hongyang Yu, et al.
Journal for Immunotherapy of Cancer|January 11, 2021
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II studyNazanin Majd, Steven G Waguespack, Filip Janku, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Expert Opinion on Pharmacotherapy|July 3, 2019
Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastomaNazanin Majd, John de Groot
Current Treatment Options in Oncology|June 26, 2019
Updates on Management of Adult MedulloblastomaNazanin Majd, Marta Penas-Prado
Advances in Experimental Medicine and Biology|April 18, 2020
Immunotherapy for Neuro-OncologyNazanin Majd, Pushan Dasgupta, John de Groot
International Journal of Molecular Sciences|January 5, 2021
Molecular Mechanisms of Treatment Resistance in GlioblastomaAlexander Ou, W K Alfred Yung, Nazanin Majd
Current Opinion in Neurology|October 1, 2019
The path forward for anti-programmed cell death-1 therapy in gliomasNazanin Majd, Carlos Kamiya-Matsuoka, John de Groot
Journal of Immunotherapy and Precision Oncology|June 6, 2022
The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in GliomasNazanin Majd, Timothy A Yap, W K Alfred Yung, et al.
International Journal of Molecular Sciences|March 19, 2020
Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment ResistanceSabbir Khan, Sandeep Mittal, Kain McGee, et al.
Cancers|July 15, 2026
Role of Surgery in the Multimodal Treatment of Pituitary Carcinoma: A Retrospective Single-Institution Case SeriesChristina Abi Faraj, Maxwell Tran, Sherise D Ferguson, et al.
Cancers|September 14, 2019
Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long StoryRand Naffouje, Punita Grover, Hongyang Yu, et al.
Journal for Immunotherapy of Cancer|January 11, 2021
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II studyNazanin Majd, Steven G Waguespack, Filip Janku, et al.
Pageof 2